The development named BIOLAUNCH involved an investment of approx. €200m in a cell culture facility to produce monoclonal antibodies.The new facility is a core element of the plan to develop the Vitry-sur-Seine site into a comprehensive biotechnology facility encompassing research, development and production activities.
Scope of PM Group Services:
- Construction Management
- Commissioning and Qualification Management